PUMA BIOTECHNOLOGY, INC. Income Statement
PBYI|9 years of annual SEC 10-K data (FY2017-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 9 fiscal years. All figures from audited SEC 10-K filings.
PUMA BIOTECHNOLOGY, INC. reported $236M in revenue and $22M in net income for FY2025. Revenue has grown at a 30.7% compound annual rate over the past 8 years.
Based on SEC 10-K filings.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $235.6M | $228.0M | $253.2M | $225.1M | $272.3M | $251.0M | $27.7M | $6.1M | $27.7M |
| Cost of Revenue | $62.7M | $55.1M | $63.7M | $39.4M | $36.8M | - | - | $5.6M | $5.6M |
| SG&A Expense | $89.9M | $90.0M | $116.3M | $118.5M | $141.6M | $146.2M | $106.7M | $53.8M | $31.8M |
| R&D Expense | $50.4M | $52.2M | $71.9M | $97.7M | $132.9M | $164.9M | $207.8M | $222.8M | $208.5M |
| Operating Income | $32.6M | $23.7M | $1.3M | -$30.4M | -$39.0M | -$94.7M | -$292.4M | -$276.6M | -$240.3M |
| Interest Expense | - | - | $12.8M | $14.0M | $15.0M | $11.0M | $720.0K | $720.0K | $720.0K |
| Income Tax | $1.1M | $455.0K | $324.0K | $207.0K | $53.0K | $17.0K | $0 | $0 | $0 |
| Net Income | $21.6M | $2.0K | -$29.1M | -$60.0M | -$75.6M | -$113.6M | -$292.0M | -$276.0M | -$239.3M |
| EPS (Basic) | $0.46 | $0.00 | -$0.72 | -$1.52 | -$75595.00 | -$0.43 | - | - | - |
| EPS (Diluted) | $0.45 | $0.00 | -$0.72 | -$1.52 | - | -$0.43 | -$7.85 | -$8.29 | -$7.45 |
| Shares Outstanding | 49.1M | 47.6M | 46.3M | 41.2M | 40.1M | 39.2M | 38.3M | 37.6M | 36.8M |
| Operating Margin | 13.9% | 10.4% | 0.5% | -13.5% | -14.3% | -37.7% | -1056.1% | -4551.5% | -867.9% |
| Profit Margin | 9.2% | 0.0% | -11.5% | -26.7% | -27.8% | -45.3% | -1054.6% | -4541.9% | -864.3% |